Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 15;18(2):803-8.
doi: 10.1016/j.bmc.2009.11.049. Epub 2009 Dec 2.

Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents

Yizhou Dong  1 , Qian Shi, Kyoko Nakagawa-Goto, Pei-Chi Wu, Susan L Morris-Natschke, Arnold Brossi, Kenneth F Bastow, Jing-Yu Lang, Mien-Chie Hung, Kuo-Hsiung Lee
Affiliations

Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents

Yizhou Dong et al. Bioorg Med Chem. .

Abstract

6-Phenyl-4H-furo[3,2-c]pyran-4-one derivatives based on neo-tashinlactone (1) were synthesized and evaluated as novel anti-breast cancer agents. Compounds 10-13, 23, 25, and 27 showed potent inhibition against the SK-BR-3 breast cancer cell line. Importantly, 25 and 27 showed the highest cancer cell line selectivity, being approximately 100-250-fold more potent against SK-BR-3 (ED(50) 0.28 and 0.44microM, respectively) compared with other cancer cell lines tested. In addition, 25 displayed low cytotoxicity against normal breast cell lines 184A1 and MCF10A. Compounds 25 and 27 merit further investigation in our continuing program to generate and develop selective anti-breast cancer agents.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of neo-tanshinlactone (1), a first generation neo-tanshinlactone analog 2, a second generation optimized analog 3, and a newly designed scaffold 4
Figure 2
Figure 2
Selective in vitro anticancer activity of 25 against SK-BR-3 breast cancer versus normal breast tissue-derived cell lines (MCF10A and 184A1). Legend: Cell line description, source and activity determination using the MTT-dye assay are described in the experimental section. Graphical data are the mean and standard deviation of values obtained from replicates in a single experiment.
Scheme 1
Scheme 1
See this image and copyright information in PMC

References

    1. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34:378–90. - PubMed
    1. Wang X, Bastow KF, Sun CM, Lin YL, Yu HJ, Don MJ, Wu TS, Nakamura S, Lee KH. Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J Med Chem. 2004;47:5816–9. - PubMed
    1. Albrand G, Terret C. Early breast cancer in the elderly: assessment and management considerations. Drugs Aging. 2008;25:35–45. - PubMed
    1. Breast Cancer Facts & Figures. 2008.
    1. Chari RVJ. Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs. Acc. Chem. Res. 2008;41:98–107. - PubMed

Publication types

MeSH terms